Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e455-e460. doi: 10.1016/j.clml.2019.11.013. Epub 2019 Nov 21.
Despite current guidelines, a significant increase in the use of core needle biopsy (CNB) has been noted. Our aims were to determine the profile of patients referred for image-guided biopsies, to assess the diagnostic yield of these biopsies, and to learn whether CNB is an effective alternative to surgical excisional biopsy (SEB).
All lymph node biopsy samples evaluated in the Department of Pathology and Laboratory Medicine from 2014 to 2017 were included. Patients' demographics, biopsy type, and final diagnosis were recorded and classified as diagnostic or nondiagnostic. The reasons for the latter were evaluated and follow-up was obtained, where available.
A total of 373 cases, 210 CNB and 163 SEB, were collected. The diagnostic yield was 79% for CNB compared to 97% for SEB. The choice of CNB versus SEB was not dependent on patient's age, gender, or clinical suspicion of malignancy. Failure to reach a diagnosis was due to insufficient or suboptimal tissue in most nondiagnostic CNBs. Lymphoma was equally diagnosed among CNB and SEB. CNB was at an advantage in diagnosing large B-cell lymphomas.
When performed adequately, CNB is a good substitute for SEB. Strict and specific guidelines need to be updated and adopted to indicate how and when it can be used, including the recommendation of concomitant complementary diagnostic laboratory testing such as flow cytometry. The latter should be readily available in order to not compromise the quality and accuracy of the diagnoses.
尽管有现行指南,但核心针活检(CNB)的使用显著增加。我们的目的是确定接受影像引导活检的患者的特征,评估这些活检的诊断率,并了解 CNB 是否是手术切除活检(SEB)的有效替代方法。
所有在病理学和检验科评估的 2014 年至 2017 年的淋巴结活检样本均包括在内。记录患者的人口统计学数据、活检类型和最终诊断,并将其分类为诊断性或非诊断性。评估后者的原因,并在有条件的情况下获取随访信息。
共收集了 373 例病例,其中 210 例为 CNB,163 例为 SEB。CNB 的诊断率为 79%,SEB 为 97%。选择 CNB 还是 SEB 并不取决于患者的年龄、性别或对恶性肿瘤的临床怀疑。大多数非诊断性 CNB 未能做出诊断的原因是组织不足或不理想。淋巴瘤在 CNB 和 SEB 中的诊断率相等。CNB 在诊断大 B 细胞淋巴瘤方面具有优势。
当正确进行时,CNB 是 SEB 的良好替代品。需要更新和采用严格和具体的指南,以指示何时以及如何使用它,包括推荐同时进行补充诊断性实验室检测,如流式细胞术。为了不影响诊断的质量和准确性,应随时提供后者。